Nivolumab and Ipilimumab in Melanoma: OpACIN Trial Follow-up
Can Second Opinions From Pathologists Improve Melanoma Diagnoses?
The Wistar Institute Awarded $12.5M Grant for Melanoma Targeted Therapies
ESMO 2019: Neoadjuvant Talimogene Laherparepvec in Advanced Resectable Melanoma
Efficacy of Nivolumab in Patients With Advanced Ocular or Mucosal Melanoma
Long-Term Outcomes With Nivolumab Plus Ipilimumab for Melanoma Brain Metastases
Long-Term Phase III Trial Results With Adjuvant Ipilimumab for Advanced Melanoma
Why Do Some Patients With Melanoma Fail to Respond to Immunotherapy?
Metastatic Melanoma: What Would You Do?
NCCN Pharmacy Updates: New and Emerging Treatment Options for Melanoma
Dermatologic Oncology Update, Issue 1, 2018
NCCN Pharmacy Updates: Treatment Considerations in Metastatic Melanoma
University of Wisconsin Carbone Cancer Center
Massachusetts General Hospital Cancer Center
Seidman Cancer Center
Helen Diller Family Comprehensive Cancer Center
Melanoma Research Foundation
NCCN Guidelines for Patients®
Melanoma International Foundation